Neurocrine Slides As Ingrezza Serious Cases Count Updated In FDA System
November 14, 2018 at 17:50 PM EST
In afternoon trading, shares of Neurocrine Biosciences have plunged more than 11% to $88.45.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions. |
|